Latest Medicine stories from Life.
RevMed's cancer treatment appears inaccessible for certain patients, while the Supreme Court maintains an essential pathway for generic drugs amid ongoing biotech developments.
As we reflect on the six-year mark since the onset of the COVID-19 pandemic, experts are evaluating how coordinated responses to domestic violence have evolved during this challenging period.
A recent presentation on Revolution Medicines' pancreatic cancer drug garnered significant attention, earning a standing ovation. However, the broader biotech sector faced challenges this week.
Despite not yet receiving approval, Revolution Medicines' pancreatic cancer drug is already the subject of discussions regarding its potential expanded applications.
NewLimit, a longevity-focused startup, has successfully raised $435 million in funding, which will support its first clinical trial targeting liver medicine.
As states increase scrutiny on corporate medicine, the telehealth sector faces significant challenges. The focus is on the corporate frameworks that support direct-to-consumer services.
Ivonescimab, a lung cancer treatment from China, garnered attention at ASCO for its potential to extend survival in patients with squamous cell lung cancer, though experts urge for trials involving a more diverse patient base.
A new study indicates that initiating hormone therapy before surgery may lead to lower relapse rates in prostate cancer patients, suggesting a shift in treatment strategies.
Recent findings presented at ASCO indicate significant progress in targeting a key component of pancreatic cancer, referred to as a 'greasy ball'.
Mark Goldsmith, CEO of Revolution Medicines, has announced the upcoming submission of daraxonrasib for FDA approval as the company begins shipping the experimental drug.
Replimune is set to make a third attempt for FDA approval of its drug, while Pfizer has recently secured a deal in China, highlighting ongoing developments in the pharmaceutical sector.
A recent study by researchers at University Medical Center Göttingen and the Max Planck Institute sheds light on the regulation of protein synthesis in mitochondria, with potential implications for understanding mitochondrial diseases.
Questions remain about the implications of Trump's Most Favored Nation deals with pharmaceutical companies, as scrutiny increases.
As the ASCO conference approaches, attention is drawn to pancreatic cancer developments, alongside significant biotech advancements including GSK's hepatitis B drug.
The FDA has postponed its decision on AstraZeneca's experimental breast cancer pill after an advisory panel voted against its approval, signaling further review is needed.
Eli Lilly has announced encouraging results from a recent clinical trial of its gene-editing therapy, indicating a significant reduction in cholesterol levels among participants.
Researchers at Osaka Metropolitan University have introduced a novel light-driven method that efficiently concentrates bacteria, potentially improving diagnostic capabilities.
Recent discussions reveal a split between EU and US advisers regarding AstraZeneca's breast cancer drug, amid notable developments in other biotech areas.
Biogen and Denali's experimental treatment for Parkinson's disease has not achieved its trial objectives, while Merck's lung cancer therapy appears to offer potential benefits.
Genentech is seeking research to bolster its position against potential pharmaceutical reforms in Washington, aiming to influence policy discussions.